Service covered by most insurance. Cash charge $119 from Quest and $75 office fee.

This test is for you if:

  • Have been asymptomatic and want to check if you were ever exposed.
  • Suspect you had Covid-19 but you haven’t been diagnosed because you had only mild symptoms.
  • Had a positive test for COVID-19 and it has been at least 14 days and you want to know if you have detectable levels of IgG antibodies.
  • Have not experienced new or worsening symptoms of COVID-19 in the past 15 days.

This is NOT for you if:

  • Have been feeling sick or have had a fever within the last 3 days. If you don’t have a health care provider we can screen you via Telemedicine and give you a referral for a walk through Covid-19 testing center.
  • Have less than 14 days since being tested for and diagnosed with COVID-19.
  • Directly exposed to COVID-19 in the past 14 days.
  • A person with a compromised immune system, a condition that makes it difficult to fight infection.

This test does not require fasting and is only available for persons 18 years of age or older.


Registered cases in NY

as of October 18

US Cases

as of October 18


as of October 18

What is the COVID-19 Antibody Test?

The COVID-19 antibody test is a blood test that provides qualitative and quantitative detection of IgG antibodies against the SARS-CoV-2 in individuals suspected of being exposed in the past, more than 14 days to COVID-19. After infection, the virus antigen stimulates the immune system to produce antibodies that can be detected in the blood.

Why the COVID-19 Antibody Test?

Serological Antibody Blood Test offers a valuable diagnostic tool in identifying patients exposed to the virus. It is NOT MEANT TO DIAGNOSE ACTIVE COVID-19 but a tool to evaluate exposure in retrospect in symptomatic and asymptomatic people. This is a blood test and it is DIFFERENT from  the Nasal Swab  RT-qPCR meant for diagnosis purposes.

Who Can Be Tested?

COVID-19 Antibody Test is recommended to be used on patients with at least 14 days after suspected or confirmed infection with the virus, in the absence of fever or any other symptomps for at least 3 days off fever lowering medication.

How do I interpret SARS-CoV-2 Serology (COVID-19) Antibody (IgG), Immunoassay results?

Results from this qualitative test for SARS CoV-2 IgG can be positive (reactive), negative (non-reactive), or, occasionally, equivocal (borderline).

A positive (reactive) result indicates detection of SARS-CoV-2 IgG, which may suggest exposure to SARS-CoV-2. It usually takes at least 10 days after symptom onset for IgG to reach detectable levels. Although the relationship between IgG positivity and immunity to SARS-CoV-2 has not yet been established, the detection of IgG antibodies may suggest an immune response to SARS-CoV-2 (COVID-19) after resolution of infection with SARS-CoV-2. Antibody tests should not be used to diagnose SARS-CoV-2 infection. Patients with symptoms should be evaluated with a molecular assay instead.

A negative (non-reactive) result indicates that SARS-CoV-2 IgG is not present at a level that is detectable by the SARS-CoV-2 Serology (COVID-19) Antibody (IgG) Immunoassay. It usually takes at least 10 days after symptom onset for IgG to reach detectable levels. However, the rate of IgG development can vary between individuals, and it is currently not known for how long IgG remains detectable after exposure to SARS-CoV-2. Negative results do not rule out COVID-19 infection, particularly in those who have been in contact with the SARS-CoV-2 virus. Follow-up testing with a molecular diagnostic assay should be considered to rule out infection if clinical condition is indicated.

An equivocal (borderline) result indicates that IgG was detected at a level or close to the threshold of the limit of detection for the test. Equivocal results may represent an early infection, detection of an IgG generated from a past infection, cross-reactivity with non-SARS CoV-2 coronavirus strains), or, in some cases, an underlying immune disorder, immunosuppression or other reasons.

Does a positive result for IgG to SARS-CoV-2 mean that the patient is immune?

Presence of IgG to SARS-CoV-2 indicates that the patient has mounted an immune response to the virus. Although the immune response may protect against reinfection, this has yet to be established. It is also not known how long antibodies to the virus will protect someone, if at all. Scientists are conducting research to answer these questions. Therefore, patients with positive IgG results should continue to take steps to protect themselves and others.

What testing technology is Quest Lab using?

The antibody testing will be based on tests from Abbott and EUROIMMUN. At the beginning of this week Abbott landed an Emergency Use Authorization for its serology test. EUROIMMUN is still in the process of submitting for an EUA, although the test is still able to be used in CLIA labs under a March FDA policy. According to Quest, Abbott reports a 99.4% specificity for its antibody test, and EUROIMMUN AG is reporting a 98.5% to 99% specificity.

The tests will be specifically aimed at testing for COVID-19 antibodies, which means the test is not meant to be used to determine whether or not a person is positive for the virus.

When the virus first hits, a patient’s body is still developing antibodies in the early days of the infection. That means that serology tests can provide negative results if administered too early.

If you or a loved one suspects you’ve already had COVID-19, please don’t hesitate to book your appointment to find out.